Categories
Tags
Authors: Jamme M, Mazeraud A PMID: 33769769 DOI: 10.1097/CCM.0000000000004926 Abstract We have read with a great interest the study by Fernandez et al (1) published in a recent issue of Critical Care Medicine. In this case-series, the authors reported the outcome of four patients admitted in ICU with coronavirus disease 2019 (COVID-19) complicated with multiorgan [...]
Categories: I-RECOVER Post-Vaccine
Tags: COVID-19, Plasmapheresis
Authors: Hamilton D, Jensen GS PMID: 33882028 Abstract Objectives: To evaluate the effects of ATP 360, a nutraceutical energy formula, in people experiencing long-term fatigue affecting daily living. To explore the use of ex vivo mitochondrial stress testing to evaluate cellular energy improvements with nutraceutical support. Study design: An open-label study design was used with [...]
Categories: I-RECOVER Long Covid, I-RECOVER Post-Vaccine
Authors: Chen T, Song J, Liu H, Zheng H, Chen C PMID: 34035353 PMCID: PMC8149409 DOI: 10.1038/s41598-021-90351-y Abstract The objective of this study was to detect the Epstein-Barr virus (EBV) coinfection in coronavirus disease 2019 (COVID-19). In this retrospective single-center study, we included 67 COVID-19 patients with onset time within 2 weeks in Renmin Hospital [...]
Categories: I-RECOVER Post-Vaccine
Tags: COVID-19
Authors: Hannan MA PMID: 34073784 doi: 10.3390/nu13061784 Abstract Mounting evidence support the potential benefits of functional foods or nutraceuticals for human health and diseases. Black cumin (Nigella sativa L.), a highly valued nutraceutical herb with a wide array of health benefits, has attracted growing interest from health-conscious individuals, the scientific community, and pharmaceutical industries. The [...]
Categories: I-PREVENT, I-RECOVER Post-Vaccine
Tags: Nigella Sativa
Authors: Seneff S, Nigh G AbstractOperation Warp Speed brought to market in the United States two mRNA vaccines, produced by Pfizer and Moderna. Interim data suggested high efficacy for both of these vaccines, which helped legitimize Emergency Use Authorization (EUA) by the FDA. However, the exceptionally rapid movement of these vaccines through controlled trials [...]
Categories: I-RECOVER Post-Vaccine
Tags: SARS-CoV-2 mRNA Vaccines
Authors: Reiter RR, Sharma R, Castillo R, Marik PE, Rodriguez AD, Cardinali DP Abstract Two highly relevant studies related to SARS-CoV-2 and coronavirus disease (COVID-19) and supporting the use of melatonin to prevent and treat this serious infection were published recently. Campos-Codo and colleagues [1] documented experimentally their claim that drugs which specifically target [...]
Categories: I-RECOVER Post-Vaccine
Authors: Rose J Abstract Following the global roll-out and administration of the Pfizer/BioNTech (BNT1 62b2) and Moderna (mRNA-1 273) COVID-1 9 vaccines 1 on December 1 7, 2020 in the United States, and of the Janssen COVID-1 9 Vaccine PF (produced by Johnson & Johnson) on April 1 st, 2021 , tens of thousands [...]
Categories: I-RECOVER Post-Vaccine
Authors: Trahtemberg U, Fritzler MJ PMID: 33928414 PMCID: PMC8084710 DOI: 10.1007/s00134-021-06408-z Abstract Coronavirus disease 2019 (COVID-19) has similarities to systemic autoimmune conditions, including an association with increased incidence of autoantibodies, including those directed toward cytokines. However, reports to date lack longitudinal assessments and have inadequate controls (i.e., comparison to different severities within COVID-19 or to [...]
Categories: I-RECOVER Post-Vaccine
Authors: Barbash IJ, Davis BS, Yabes JG, Seymour CW, Angus DC, Kahn JM PMID: 33872042 PMCID: PMC8844885 DOI: 10.7326/M20-5043 Abstract Background: Medicare requires that hospitals report on their adherence to the Severe Sepsis and Septic Shock Early Management Bundle (SEP-1). Objective: To evaluate the effect of SEP-1 on treatment patterns and patient outcomes. Design: Longitudinal [...]
Categories: I-RECOVER Post-Vaccine
Tags: Sepsis
Authors: Poenaru S, Abdallah SJ, Corrales-Medina V, Cowan J PMID: 33959278 PMCID: PMC8060761 DOI: 10.1177/20499361211009385 Abstract Coronavirus disease 2019 (COVID-19) is a viral infection which can cause a variety of respiratory, gastrointestinal, and vascular symptoms. The acute illness phase generally lasts no more than 2-3 weeks. However, there is increasing evidence that a proportion of [...]
Categories: I-RECOVER Post-Vaccine
Tags: Chronic Fatigue Syndrome, COVID-19